Table 1 The clinical characteristics between survivors and non-survivors

Age, years, median (IQR)

63 (55–69)

66 (61–72)

0.26

Gender (Male/Female)

34/27

8/8

0.682

Time from onset to admission (days)

5 (4–7)

5 (5–7)

0.969

Duration of hospital admission (days)

12 (9–16)

4.5 (1.2–7.7)

< 0.001

30 (49.1)

16 (100)

< 0.001

59 (96.7)

16 (100)

0.463

34 (55.7)

11 (68.7)

0.347

14 (22.9)

1 (6.2)

0.133

26 (42.6)

10 (62.5)

0.156

52 (85.2)

16 (100)

0.102

29 (47.5)

9 (56.2)

< 0.001

 Fasting blood glucose (mmol/L)

6.9 (5.3–9.5)

10.1 (12.9)

0.015

 Leukocytes (×10⁹/L)

2.32 (1.6–3.9)

2.3 (1.4–3.5)

0.551

 Neutrophils (×10⁹/L)

1.3 (0.8–2.3)

1.2 (0.8–2.3)

0.90

 Platelet (×10⁹/L)

46 (34–68)

40 (25–52)

0.189

 Procalcitonin (ng/ml)

0.11 (0.05–0.22)

0.54 (0.15–0.89)

0.001

 C-reactive protein (mg/L)

3.1 (0.8–9.2)

4.7 (2.0–12.8)

0.177

 Aspartate aminotransferase (U/L)

120 (89.5–232)

457 (128–706)

0.005

 Alanine aminotransferase (U/L)

75 (43.5–92)

97 (59–178)

0.034

 Creatinine (μmol/L)

67.5 (58–88.1)

94.2 (76–166)

0.001

 lactate dehydrogenase (U/L)

827 (562–1556)

1720 (1008–5761)

0.002

 Creatine kinase (U/L)

316 (116–731)

580 (185–3563)

0.096

 PT, secs.

13.5 (12.8–13.9)

13.6 (12.8–15.2)

0.397

 APTT, secs.

50.4 (42.8–54.8)

67.7 (54.4–85.5)

< 0.001

 D-Dimer (μg/mL)

1.87 (1.27–3.61)

6.7 (2.8–15.7)

< 0.001

 Fibrin degradation product (μg/mL)

5.98 (3.77–12.3)

19.7 (8.9–63.2)

0.001

99 (30–681)

99.5 (55–392)

0.56

559 (27–2000)

581 (105–1576)

0.95

 Interleukin-1β (pg/ml)

8.1 (5.0–13.5)

22.7 (10.9–36.0)

< 0.001

 Interleukin-2R (U/ml)

1106 (841–1381)

1714 (1267–2803)

0.001

 Interleukin-6 (pg/ml)

10.8 (5.0–16.3)

68.7 (20.4–140.0)

< 0.001

 Interleukin-8 (pg/ml)

20.5 (14.9–32.4)

73.5 (34.4–232.5)

0.001

 Interleukin-10 (pg/ml)

36 (10.4–63.6)

117 (53.8–275.5)

< 0.001

 Tumor necrosis factor-α (pg/ml)

18.4 (14.8–24.0)

47.4 (27.3–116.3)

< 0.001